Next-Generation DNA Sequencer Platform Is Small and Affordable

A benchtop next-generation DNA sequencing platform is ideally suited for labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial-genome sequencing, metagenomic analysis, as well as novel pathogen detection.

The GS Junior System includes a suite of high-performance data analysis software, offering a solution for scientists who are less experienced in DNA sequencing technologies and bioinformatics. The software package includes tools for de novo genome and transcriptome assembly and mapping, as well as amplicon variant analysis for the identification of rare variants in targeted sequencing studies.


Roche (Basel, Switzerland) announced the global launch of the GS Junior System, the company's new DNA sequencing platform. Developed by 454 Life Sciences (Branford, CT, USA), a Roche company, the system provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency, and price competitiveness, small and medium sized laboratories worldwide will have access to Roche's state-of-the-art sequencing capabilities at an affordable price.

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double-digit growth expected for the next several years.

Roche's Genome Sequencer FLX System has enabled hundreds of scientific discoveries, including the identification of novel pathogenic viruses, the analysis of ancient DNA from Neanderthal man and the wooly mammoth, and the characterization of microbial communities in the human gut.

"Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turnaround time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications,” said Daniel O'Day, COO of Roche Diagnostics (Indianapolis, IN, USA).

Roche is a leader in research-focused healthcare with combined strengths in diagnostics and pharmaceuticals. It is also a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

Related Links:
Roche
454 Life Sciences
Roche Diagnostics